INTRODUCTION {#s1}
============

Arising from the epithelial layer of urinary bladder, bladder cancer is one of the most common malignant cancers in the world and its incidence has gradually increased, listed as the sixth most frequent form of cancer in 2013 \[[@R1]\]. About 110,500 males and 70,000 females are diagnosed as new cases every year, causing about 38,200 and 17,000 deaths in the European Union and in the USA, respectively \[[@R2]\]. About 80% patients with bladder cancer are diagnosed as non-muscle-invasive bladder cancer when first diagnosed, and about 80% of these patients experience a recurrence after initial treatment within 5 years \[[@R3]\]. There are a few treatments for bladder cancer, for example, intravesical Bacillus Calmette-Guérin (BCG) is the main but controversial treatment because about 30%-40% of patients fail to respond to it \[[@R4]\]. Furthermore, neoadjuvant chemotherapy (NAC) also provides a significant survival benefit for the treatment of bladder cancer but it is limited because of chemotherapy-related toxicity and the delay of final local treatment \[[@R5]\].

Forkhead box class O (FOXO) is the subgroup O of forkhead box (FOX) transcription factors, which includes 4 members, FOXO1, FOXO3, FOXO4 and FOXO6 \[[@R6]\]. FOXOs play a crucial role in cell processes like cell proliferation, apoptosis, DNA repair and stress response \[[@R7]\]. FOXOs are closely related to the growth of cervical cancer cells through regulating the expression of certain proteins or genes \[[@R8]\]. FOXOs have highly conserved forkhead DNA-binding domain \[[@R9]\]. Combination of FOXO1 and p53 can provide relevant prognostic information on progression and recurrence of bladder cancer \[[@R10]\]. The transcription factor FOXO3 is an effective tumor suppressor; dysregulation of FOXO3 is associated with cancer initiation and progression \[[@R11]\]. FOXO3 and FOXO4 may play an important role in cell apoptosis and the regulation of cell cycle in fetal membrane rupture \[[@R12]\]. FOXO4 is known as a tumor suppressor protein, which is closely related to the metastasis of cholangiocarcinoma \[[@R13]\]. However, given the inadequate data about the relationship between FOXOs and bladder cancer, we explored the expression of FOXOs in bladder cancer tissue and paracancerous tissue, so as to elucidate the correlation between expression of FOXOs with clinicopathological features and prognosis of bladder cancer.

RESULTS {#s2}
=======

Demographic of patients {#s2_1}
-----------------------

A cohort of 276 patients diagnosed with bladder cancer were finally enrolled, among whom 218 were males and 58 were females, with a median age of 57 (range: 21-76) years.

Expressions of FOXOs in bladder cancer tissue and normal bladder tissue {#s2_2}
-----------------------------------------------------------------------

The expressions of FOXOs protein in bladder cancer tissue and paracancerous tissue were detected by IHC (Figure [1](#F1){ref-type="fig"}). The positive staining of FOXOs was mainly located in cytoplasm, and colored brown-yellow. Bladder cancer tissues exhibited more FOXOs-negative cells than paracancerous tissue. In the 276 tumor tissue samples, negative expression of FOXO1 was found in 150 cases, weakly positive in 34 cases, moderate level in 62 cases, and strongly positive in 30 cases; negative expression of FOXO3 was found in 134 cases, weakly positive in 44 cases, moderately positive in 36 cases, and strongly positive in 62 cases; negative expression of FOXO4 was found in 118 cases, weakly positive in 60 cases, moderately positive in 52 cases, and strongly positive in 46 cases.

![Expressions of FOXOs in cancer and paracancerous tissue, detected by immunohistochemistry\
The expressions of FOXO1, FOXO3 and FOXO4 are shown. The density of staining includes negative, weakly positive, moderately positive, strongly positive and normal positive. FOXO, forkhead box class O.](oncotarget-08-96313-g001){#F1}

Association between protein expression of FOXOs and clinical features of bladder cancer {#s2_3}
---------------------------------------------------------------------------------------

Significant differences were found in comparisons of the expressions of FOXOs with histological grade, clinical stage and lymph node metastasis (all *P* \< 0.05). However, no significant difference was found in comparisons of low expression of FOXOs with patients' gender and age, as well as tumor size and number (all *P* \> 0.05) (Table [1](#T1){ref-type="table"}).

###### Cox regression model of multiple variables for bladder cancer prognosis

                          Univariate analysis   Multivariate analysis                                             
  ----------------------- --------------------- ----------------------- ------- --------- ------- ------- ------- ---------
  Gender                  0.876                 0.571                   1.344   0.545                             
  Age                     0.843                 0.596                   1.194   0.337                             
  Tumor size              1.178                 0.840                   1.654   0.342                             
  Tumor number            1.369                 0.967                   1.939   0.077                             
  Histological grade      1.348                 0.928                   1.958   0.116     1.375   0.911   2.074   0.129
  Clinical stage          2.814                 1.918                   4.128   \<0.001   1.861   1.217   2.844   0.004
  Lymph node metastasis   2.914                 2.067                   4.109   \<0.001   1.866   1.284   2.712   0.001
  Expression of FOXO1     0.085                 0.050                   0.144   \<0.001   0.333   0.170   0.654   0.001
  Expression of FOXO3     0.135                 0.088                   0.205   \<0.001   0.434   0.261   0.724   0.001
  Expression of FOXO4     0.113                 0.076                   0.168   \<0.001   0.314   0.196   0.505   \<0.001

Cox, Cox\'s proportional hazards regression model; FOXO, forkhead box class O.

Expression of FOXOs mRNA in bladder cancer tissue and paracancerous tissue {#s2_4}
--------------------------------------------------------------------------

As shown in Figure [2](#F2){ref-type="fig"}, FOXOs were over-expressed in paracancerous tissue, and their expressions are significantly higher than in bladder cancer tissue (*P* \< 0.05). Compared with low-grade patients, the expressions of FOXOs in high-grade patients were significantly decreased (*P* \< 0.05). Importantly, the FOXOs expressions in patients with superficial bladder cancer were higher than patients with invasive bladder cancer (*P* \< 0.05). Moreover, the FOXOs expressions in patients without lymph node metastasis were significantly higher than patients with lymph node metastasis (*P* \< 0.05).

![The mRNA expression levels of FOXOs in bladder cancer tissue and paracancerous tissue, determined by quantitative real-time polymerase chain reaction (qRT-PCR)\
The q-PCR assay was used to test the mRNA expression of FOXO1, FOXO3 and FOXO4 in both normal and tumor tissues, and the results showed that FOXO1, FOXO3 and FOXO4 in tumor tissues had a lower expression than normal tissues; ^\*^, *P* \< 0.05 compared with paracancerous; FOXO, forkhead box class O.](oncotarget-08-96313-g002){#F2}

Diagnostic value of mRNA expression of FOXOs in bladder cancer {#s2_5}
--------------------------------------------------------------

The sensitivity and the specificity of mRNA expression of FOXOs in bladder cancer were shown in Table [2](#T2){ref-type="table"}. The ROC curve was drawn using sensitivity as the ordinate and specificity as the abscissa, and the area under the curve was shown in Figure [3](#F3){ref-type="fig"} (*P* \< 0.05). The mRNA expressions of FOXO1/3/4, as the cutoff values for diagnosing, were 1.475, 1.305, 1.295, respectively, and there was the highest sensitivity and specificity when detected by qRT-PCR. When the mRNA expressions of FOXO1/3/4 were less than 1.475, 1.305 and 1.295, respectively, we could primarily diagnose the patient with bladder cancer.

###### Correlation of FOXOs expressions of and clinical features

  Group                   n = 276   FOXO1 expression   FOXO3 expression   FOXO4 expression                                  
  ----------------------- --------- ------------------ ------------------ ------------------ ----- ----- ------- ---- ----- ----------
  Age (year)                                                                                                                
   \<60                   160       80                 80                 0.089              72    88    0.166   76   84    0.061
   ≥60                    116       70                 46                 62                 54    42    74                 
  Gender                                                                                                                    
   Male                   218       120                98                 0.652              104   114   0.586   92   126   0.719
   Female                 58        30                 28                 30                 28    26    32                 
  Tumor size                                                                                                                
   \< 3cm                 146       80                 66                 0.875              76    70    0.217   64   82    0.7
   ≥ 3cm                  130       70                 60                 58                 72    54    76                 
  Tumor number                                                                                                              
   Single                 186       102                84                 0.814              92    94    0.663   80   106   0.901
   Multiple               90        48                 42                 42                 48    38    52                 
  Histological grade                                                                                                        
   Low grade              90        38                 52                 0.005              32    58    0.003   27   63    0.004
   High grade             186       112                74                 102                84    91    95                 
  Clinical stage                                                                                                            
   T~A~+T~1~              124       48                 76                 \<0.001            46    78    0.001   42   82    0.007
   T~2~\~T~4~             152       102                50                 88                 64    76    76                 
  Lymph node metastasis                                                                                                     
   No                     196       90                 106                0.002              84    112   0.003   66   130   \< 0.001
   Yes                    80        60                 20                 50                 30    52    28                 

FOXO, FOXO, forkhead box class O.

![The ROC curves of FOXOs in patients with bladder cancer\
The ROC curve was drawn using sensitivity as the ordinate and specificity as the abscissa, and the area under curve was shown. The mRNA expressions of FOXO1/3/4, as the value of cutoff for diagnosing, were 1.475, 1.305, 1.295, respectively, by which we could confirm a patient with bladder cancer. ROC, receiver operating characteristic; FOXO, forkhead box class O.](oncotarget-08-96313-g003){#F3}

Association between the expression of FOXOs and the prognosis of bladder cancer {#s2_6}
-------------------------------------------------------------------------------

The association between expression of FOXOs and survival time of patients with bladder cancer was analyzed by the Kaplan-Meier method. Results indicated that the survival curve of the group with low expression of FOXOs was below the one with high expression and the overall survival of the low-expression FOXOs was shorter than the high-expression FOXOs (*P* \<0.05, Figure [4](#F4){ref-type="fig"}).

![The Kaplan-Meier curve of associations between expression of FOXOs and survival time of patients with bladder cancer\
The results of survival analysis revealed that patients with positive expressions of FOXO1 had higher survival than patients with negative expressions **(A)**. More importantly, similar results can be seen in FOXO3 and FOXO4 **(B and C)**, suggesting FOXO1, FOXO3 and FOXO4 may play a negative role to promote the progression of bladder cancer. A, FOXO1; B, FOXO3; C, FOXO4; FOXO, forkhead box class O.](oncotarget-08-96313-g004){#F4}

Evaluation of risk factors for prognosis of bladder cancer {#s2_7}
----------------------------------------------------------

The Cox regression model was used to analyze individual variables which may affect the prognosis of bladder cancer. Except for the expression of FOXOs, other variables included gender, age, tumor size, number, grade, stage and lymph node metastasis. Univariate analysis indicated that the overall survival was related to histological grade, clinical stage, lymph node metastasis and expression of FOXOs. Further multivariate analysis was used to analyze these statistically significant variables; the results indicated that lymph node metastasis, high clinical stage, and low expression of FOXOs were the risk factors which affect the prognosis of bladder cancer (both *P* \< 0.05) (Table [3](#T3){ref-type="table"}).

###### ROC curve of FOXOs mRNA expressions

  Variable   Sensitivity (%)   Specificity (%)   AUC     *P*        cutoff
  ---------- ----------------- ----------------- ------- ---------- --------
  FOXO1      92.9              86.2              0.948   \< 0.001   1.475
  FOXO3      95.7              98.6              0.979   \< 0.001   1.305
  FOXO4      95.7              94.9              0.974   \< 0.001   1.295

ROC, receiver operating characteristic; AUC, area under the curve; FOXO, FOXO, forkhead box class O.

DISCUSSION {#s3}
==========

In the present study, we explored the correlation between the expression of FOXOs and prognostic factors in bladder cancer. We found that expression of FOXOs increased with higher histological grade and clinical stage, while significantly decreased in patients with lymph node metastasis. Low expression of FOXOs could be regarded as an individual risk factor to predict bladder cancer prognosis.

Bladder cancer is a heterogeneous disease. The disease is prone to relapse in about 70% of patients although not life threatening, and muscle-invasive with high risk of distant metastases and death in the other 30% of patients" \[[@R14]\]. The survival rate after surgery for 5 years was about 25%-80%, which is even worse in patients with lymph node metastasis \[[@R15]\]. Therefore, understanding the biological mechanism underlying bladder cancer may help find new biomarkers for establishing effective strategy in prevention, early diagnosis and treatment of bladder cancer. A former study found that FOXOs are involved in many processes such as tumor suppression and cell apoptosis \[[@R16]\]. In our study, compared with bladder cancer tissue, overexpression of FOXOs was found in paracancerous tissue. The FOXOs family including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4), are characterized by a conserved DNA-binding domain \[[@R17]\]. In animal experiments, mice without somatic cells of FOXO1, FOXO3a, and FOXO4 led to the progression of hemangiomas and thymic lymphomas, which proved the possible function of FOXO to serve as the redundant inhibitors of tumor growth \[[@R18]\]. The low-expressed FOXOs play a crucial role in tumor progression via down-regulation of target genes related to stress resistance, cell cycle arrest and cell apoptosis \[[@R6]\]. In bladder cancer, down-regulation of FOXO1 was closely connected with worse results like high risk of recurrence, especially in high-grade tumors \[[@R10]\]. A previous study suggested that the activation of FOXO3a was related to lymph node metastasis and poor prognosis in patients with breast cancer \[[@R19]\].

Furthermore, we found that low expression of FOXOs is related to higher histological grade, clinical stage, and lymph node metastasis. FOXO3a can regulate motility of urothelial cancer by down-regulating Twist2 and YB-1, and up-regulating E-cadherin \[[@R20]\]. Yu et al found that Nkx 2.8, as one of the tumor suppressor, inhibited bladder cancer proliferation through up-regulating the expression of FOXO3a \[[@R21]\]. The expression of inactivated form of phosphorylated FOXO1 was inversely related to lymph node metastasis and positively associated with a longer survival time in patients with early-stage gastric cancer \[[@R22]\]. The expression of FOXO1 was enhanced in superficial bladder cancer when compared with invasive cancer, and compared with the high-grade group (grade 3), expression of FOXO1 was higher in low-grade bladder cancer (grade 1-2) \[[@R23]\]. Moreover, the expression of nuclear FOXO3a was related to a low histological grade, which supported the inhibitory effect of FOXO3a \[[@R24]\]. Additionally, patients with high expression of FOXOs could survive longer than those with low expressions of FOXOs. FOXOs can facilitate DNA repair through regulating defined transcriptional programs and executing transcription-independent functions, contributing to genomic stability and further longevity and tumor-free survival \[[@R25]\]. For these reasons and former studies, we may infer that in cancer cells, FOXOs could serve as a suppressor of tumor progression. Understanding the regulation of FOXOs may yield alternative methods for the diagnosis and treatments of bladder cancer. However, the detailed mechanism of FOXOs still needs further investigation.

In conclusion, expression of FOXOs was significantly decreased with higher histological grade and clinical stage and lymph node metastasis, and low expression of FOXOs was found as one of the individual risk factors of bladder cancer prognosis. Thus, FOXOs may serve as a new biomarker for diagnosing bladder cancer. However, due to the complicated individual risk factors of bladder cancer, adequate experimental data to elucidate the specific mechanism of FOXOs in bladder cancer are still lacking, and further studies are needed.

MATERIALS AND METHODS {#s4}
=====================

Study subjects and grouping {#s4_1}
---------------------------

Between June 2009 and June 2013, a total of 276 patients diagnosed with bladder cancer were enrolled into the study. All the patients were treated with surgical treatment (transurethral resection or radical cystectomy for bladder cancer). Besides, 35 samples of the corresponding non-cancerous mucosa, which was 2 cm away from the tumor were collected for the study. Inclusion criteria: first, patients were diagnosed with transitional cell carcinoma (TCC) by pathologic examination; second, complete clinical data, pathological data and follow-up data were available; third, patients did not receive any chemotherapy or radiotherapy, including intravesical instillation. The follow-up time was 3 years, with the first 2 years being followed up every 3 months and every 6 months in the last year. Collected clinical data of patients included age, gender, survival time, tumor size and number, tumor grade, tumor stage, lymph node metastasis, etc. This study was approved by the ethics committee of China-Japan Union Hospital of Jilin University, and all the patients signed the informed consent.

Immunohistochemistry (IHC) {#s4_2}
--------------------------

Bladder cancer tissue and normal bladder tissue were fixed, dehydrated, embedded in paraffin, and sliced up (the thickness of slice was 4 μm). The sections were blocked with endogenous peroxidase with 1% H~2~0~2~, put into antigen repair solution, heated to 97°C for 15 min and cooled naturally. The samples were incubated with normal goat serum (Diagnostics Scotland, Edinburgh, UK) blocking solution at room temperature for 20 min, with the excess solution threw away. Then the sections were added with FOXO1 antibody (Abcam Company, Cambridge, MA, USA), FOXO3 antibody (Bioss Company, Beijing, China), FOXO4 antibody (Abcam Company, Cambridge, MA, USA) successively and incubated overnight at 4°C. Next, biotinylated secondary antibody (Zhongshan Golden Bridge Company, Beijing, China) was added and the tissues were incubated at 37°C for 40 min, followed by developing by diaminobenzidine (DAB) (Zhongshan Golden Bridge Company, Beijing, China). Positive sections were regarded as positive controls, and phosphate buffer saline (PBS) was used in place of the first antibody as negative controls. Multifunctional Real Color Image Analysis System (Media Cybernetics Company, Maryland, USA) was used for analysis. Five high power fields were selected randomly in each section, and the expression was calculated based on positive staining rate and color depth: the cells were scored according to the color depth: 0 is colorless, 1 is pale yellow, 2 is brown, and 4 is dark brown. Cells were also scored based on the percentage of staining cells in counting cells: 0 is no positive cells; 1, 2 and 3 indicate \< 10%, 11%-50%, and \> 50% positive staining cells, respectively. By multiplying these two together, 0 is negative, 1-2 indicate weakly positive, 3-4 indicate moderately positive, 5-12 indicate strongly positive. Color depth and relevant score of each sample were evaluated independently by two pathologists in a double-blind way. The average number was used as the protein expression (expression intensity) of the corresponding sample.

Quantitative real-time polymerase chain reaction (qRT-PCR) {#s4_3}
----------------------------------------------------------

The total RNAs from the cancer tissue and normal bladder tissue were extracted by the Trizol total RNA extraction kit (Aidlab Company, Beijing, China). The RNA samples (5 μL) were collected and diluted 20 times by ultra-pure RNase-free water. The absorbance at 260 nm and 280 nm on ultraviolet spectrophotometer was observed and the concentration and the purity of RNA were measured. The ratio of OD260/OD280 between 1.7 and 2.1 indicates a relatively high RNA purity to meet the needs of subsequent experiments. Complementary DNA (cDNA) was synthesized by reverse transcription reaction, and qRT-PCR experiment was conducted using ABI7500 quantitative PCR instrument (Applied Biosystem, Grand Island, NY, USA), the reaction conditions were as follows: pre-denaturation at 95°C for 10 min, 45 PCR cycles (95°C for 15 s, 60°C for 1 min). The primer sequences are shown in Table [4](#T4){ref-type="table"}. β-actin was regarded as internal reference, and 2^-ΔΔCt^ presented the ratio of gene expression between the observation group and the control group. The formula was ΔΔCT = ΔCt ~observation\ group~ - ΔCt ~control\ group~, ΔCt = Ct ~target\ gene\ -~ Ct ~β-actin~. The threshold cycle (CT) was the amplification cycles when real-time fluorescence intensity reached the set threshold, and at this point, the growth rate was logarithmic.

###### RT-PCR Primer sequences for qRT-PCR

  Gene      Primer sequence
  --------- ----------------------------------
  FOXO1     5'-AACCTGGCATTACAGTTGGCC -3'
            5'-AAATGCAGGAGGCATGACTACGT-3'
  FOXO3     5'-AAGCCAGCTACCTTCTCTTCCA -3'
            5'- GTGGCTAAGTGAGTCCGAAGTGA-3'
  FOXO4     5'-CCCGACCAGAGATCGCTAAC-3'
            5'-TCCGTGTGTACCTTTTCCCC-3'
  β-actin   5'- CTCCTTAATGTCACGCAGGATTTC -3'
            5'- GTGGGGCGCCCCAGGCACCA-3'

qRT-PCR, quantitative real-time polymerase chain reaction; FOXO, forkhead box class O.

Statistics {#s4_4}
----------

The Statistical Program for Social Sciences (SPSS) 19.0 software (SPSS, IBM, West Grove, PA, USA) was used for data analysis. Measurement data were expressed as mean ± standard deviation, and enumeration data were expressed as rate or percentage. Comparisons of measurement data and enumeration data were statistically analyzed with the Student-t test and the χ^2^ test, respectively. Diagnostic efficiency was analyzed by receiver operating characteristic (ROC) curve. The relationship between the survival time of patients after surgery and expression of FOXOs was analyzed by the Kaplan-Meier method. The individual variables which affect the survival of patients with bladder cancer were evaluated by Cox proportional hazard regression model. The statistical significance of univariate and multivariate Cox regression model was confirmed by Wald\'s test. All tests were two-tailed, with the level of significance set to *P* \< 0.05.
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